VERTEX PHARMACEUTICALS INC / MA Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $13.08 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for the quarter ending 2018-09-30 was $3.10M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for the quarter ending 2018-03-31 was -$21.90M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2020 was $13.08M, a 22.62% increase from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2019 was $10.67M, a 28.35% increase from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2018 was $8.31M, a 27.83% increase from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2017 was $6.50M, a 7459.30% increase from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 9 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month |
|---|---|---|---|
| 2020-12-31 | $13.08M 10-K · filed 2021-02-11 | ||
| 2019-12-31 | $10.67M 10-K · filed 2021-02-11 | ||
| 2018-12-31 | $8.31M 10-K · filed 2021-02-11 | ||
| 2018-09-30 | $3.10M 10-Q · filed 2018-10-25 | -$13.70M 10-Q · filed 2018-10-25 | |
| 2018-03-31 | -$21.90M 10-Q · filed 2019-05-01 | ||
| 2017-12-31 | $6.50M 10-K · filed 2020-02-13 | ||
| 2016-12-31 | $86.00K 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |